Neurologists & MS Drug Payments: What You Need to Know
- A recent analysis of Medicare data, published in the open access journal BMJ Open, found that nearly 80% of US neurologists prescribing drugs for multiple sclerosis (MS) received...
- Multiple sclerosis is a chronic, often lifelong condition requiring ongoing treatment.
- Researchers analyzed publicly available data from the Centers for Medicare & Medicaid (CMS) Open Payments platform, linking it to Medicare Part D prescription data.
“`html
Pharma Payments to Neurologists and MS Drug Prescriptions: A 5-Year analysis
Table of Contents
What Happened?
A recent analysis of Medicare data, published in the open access journal BMJ Open, found that nearly 80% of US neurologists prescribing drugs for multiple sclerosis (MS) received at least one payment from the pharmaceutical industry between 2015 and 2019. The study revealed a clear link between the volume of payments received and the likelihood of prescribing drugs from the paying company, particularly when payments were larger, sustained, and recent.
Why this Matters: The Context of MS Drug Costs
Multiple sclerosis is a chronic, often lifelong condition requiring ongoing treatment. Effective therapies are typically continued indefinitely unless a patient’s clinical response changes.Importantly, MS drug prescriptions represent a meaningful expense for Medicare, despite accounting for a relatively small proportion of total claims. This makes the prescribing practices within this market particularly vital to scrutinize.
Key Findings of the Analysis
Researchers analyzed publicly available data from the Centers for Medicare & Medicaid (CMS) Open Payments platform, linking it to Medicare Part D prescription data. Their analysis included 7,401 neurologists who prescribed disease-modifying therapies (DMTs) for at least one year, issuing a minimum of 11 prescriptions, and covering 20 dmts manufactured by 10 companies.
- Prevalence of Payments: 5,809 (78.5%) of neurologists received a total of 626,290 industry payments, amounting to US$163.6 million.
- Multiple Payers: 4,999 (67.5%) neurologists received payments from two or more companies.
- Payment Amounts: The average individual payment was US$779. However, 10% of recipients received US$155.7 million – representing 95% of the total amount – suggesting targeted payments to high-volume prescribers.
- Payment Types: Higher prescription volumes correlated with a greater likelihood of receiving payments for consulting services, speaking engagements, travel/accommodation, and, most commonly, food and drink.
- Correlation with Prescriptions: The amount received was positively associated with prescription volume.
Types of Industry Payments analyzed
The researchers categorized payments into three main types:
- Research Payments: Funding for clinical trials or othre research activities.
- Ownership and Investment Interests: Financial stakes in pharmaceutical companies.
- General Payments: A broad category including consulting fees,speaking fees,travel/accommodation expenses,and meals.
The study focused primarily on general payments to neurologists.
Who is Affected?
This study has implications for several stakeholders:
- Patients with MS: Potential for biased prescribing practices could impact treatment choices and outcomes.
- Neurologists: The findings raise ethical considerations regarding potential conflicts of interest.
- Medicare/Healthcare System: Increased costs due to potentially influenced prescribing.